{"entity":{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","aka":[],"tldr":"Eikon Therapeutics is a Nasdaq-listed United States biotechnology company running 6 late-stage cancer trials of EIK1001, EIK1004-001 (IMP1707-001) and IMP1734 in melanoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer.","summary":"Eikon Therapeutics, based in Millbrae, California, the United States, is a biotechnology company. A drug discovery company that also has offices in New York and Jersey City and lists clinical-stage oncology, immunology and neuroscience programmes on its pipeline page, including TLR7/8, PARP1, PARP1-CNS penetrant, AR, VCP and AR-v7 targeted programmes. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing EIK1001, EIK1004-001 (IMP1707-001), IMP1734 and EIK1005 in melanoma, non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, colorectal cancer and endometrial cancer. The largest, NCT07365319 (A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer), plans to enrol 750 participants. Eikon went public on the Nasdaq Global Select Market in February 2026, selling 21,177,600 shares at USD 18.00 in its initial public offering under the symbol EIKN. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website and the IPO prospectus.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.eikontx.com"},{"label":"SEC: IPO prospectus (4 February 2026)","url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526039375/d99350d424b4.htm"},{"label":"ClinicalTrials.gov: trials led by Eikon Therapeutics","url":"https://clinicaltrials.gov/search?lead=Eikon%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","nsclc","gastric","colorectal","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["eik1001","eik1005","imp1734"],"companies":["lux-capital"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06246110","nct06907043"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026 from SEC EDGAR: S-1 filed 9 January 2026, final prospectus 5 February 2026 and a 10-K for 2025. No acquisition or merger found. The company website returned HTTP 403 to an automated check."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Millbrae, California","country":"US","companyType":"biotech","website":"https://www.eikontx.com","ticker":"NASDAQ: EIKN","stage":"public","investors":[],"funding":[{"round":"IPO","year":2026,"amountUsd":381196800,"source":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526039375/d99350d424b4.htm","note":"21,177,600 shares at USD 18.00, prospectus dated 4 February 2026; gross figure before underwriting discounts and the 30-day option on 3,176,640 further shares"}]},"route":"/companies/eikon-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/"},{"id":"eik1005","kind":"drug","name":"EIK1005","route":"/drugs/eik1005/"},{"id":"imp1734","kind":"drug","name":"IMP1734","route":"/drugs/imp1734/"}],"company":[{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/"}],"trial":[{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/"},{"id":"nct06246110","kind":"trial","name":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","route":"/trials/nct06246110/"},{"id":"nct07365319","kind":"trial","name":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer","route":"/trials/nct07365319/"},{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/"},{"id":"nct07262619","kind":"trial","name":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic","route":"/trials/nct07262619/"},{"id":"nct06697301","kind":"trial","name":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma","route":"/trials/nct06697301/"}]}}